New CEO with Great ViCEO has a great vision, but legacy culture limits progression - Recensione dipendente - Dipendente anonimo presso LifeArc

3,0
9 nov 2025
Dipendente anonimo
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

The new CEO is genuinely kind, approachable, and deeply committed to translating science into meaningful clinical impact for families and patients with rare diseases. Clear organisational purpose and focus on advancing research into real-world applications. Friendly colleagues in many teams and a generally supportive working environment. The CEO takes time to listen, holding drop-in sessions across 3 sites to understand staff needs.

Svantaggi

A legacy culture where some long-standing employees resist change and make it harder for new staff to progress. Career progression opportunities are limited and often based on historic structures rather than performance or potential. Some roles are filled internally without being advertised, leading to a lack of transparency. In certain departments, there are few or no clear pathways for advancement but this is a structural rather than leadership issue. The organisation remains a bit hierarchical, though Sam is actively working to make it more open and collaborative.

Esplora altre recensioni su LifeArc

1,0
2 mag 2026
Dipendente anonimo
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good pay and benefits but it comes at the risk of redundancy at any point depending on what the c-suite suddenly decide to focus on.

Svantaggi

Incompetent leadership, especially the CEO, and toxic culture at the top. Workplace bullying and contracts/jobs being awarded based on who is friends with who.

1
2,0
17 feb 2026
Consiglia
Gradimento del CEO
Pronostico commerciale

Vantaggi

Good salary and benefits (annual leave). Good work life balance if your line manager is not a micromanager. Nice colleagues across different departments. Some work is inspiring.

Svantaggi

As other reviews pointed out, people disappear in silence. The strategy is a word that you hear daily but everyone knows it changes with a single shake up in the Exec team. This leaves the Science direction completely unsustainable in the long term. Apparently we want to see patient impact sooner but unfortunately money is spent on new buildings leases. The new CEO just runs with the initial idea she had since joining and pulls the rug out from under people's feet. Then, there is a bit of resistance from staff and a quasi U-turn. We have been told that we are doing too much as an organisation (fair point) yet we added a whole new clinical layer. Did not like the phrase "translational research" - get rid of it even though it was the main identity point for the organisation for a while. Quite a few redundancies of lab scientists but then loads of recruitment activity a year later even though we don't want to increase the headcount? Surely that will lead to more redundancies later on especially that there is some overlap in various teams' remit with some team leaders being super territorial after building their "empires". As a general rule, people are told that their projects are discontinued and are then kept in the dark whether there is future opportunities/redeployment until the last minute despite months of reassurance and "planning" next steps. Things are much worse for contractor/temps. Don't get me wrong - you are considering taking a job here, it can still be a nice place to work, especially if you are unhappy in your current workplace. However, don't count on the organisation being a long term source of job satisfaction.

3
Vedi recensioni per: Utile|Valutazione|Data|Tutto